Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FzioMed has been awarded a small business innovation research phase I grant by the US National Institutes of Health to support development of a novel injectable product for acceleration of bone healing in spinal fusion procedures.
Subscribe to our email newsletter
The grant will support preclinical studies to determine the optimal Oxiplex gel for injectable delivery of a bone growth peptide, and to evaluate the efficacy of the peptide in bone healing.
Oxiplex is a patented, synthetic biomaterial that can be formulated for use in a variety of medical applications. FzioMed recently acquired the exclusive, worldwide rights to a patented platform of novel, synthetic bone growth peptides that have been shown to have osteoinductive properties. The company is combining the peptides into Oxiplex gels to create products for use in orthopedic and spinal procedures.
“The osteoinductive materials currently used in spinal fusions can be expensive to manufacture and may not provide optimum performance,” said John Krelle, president and COO of FzioMed. “We believe that by combining synthetic peptides with injectable, synthetic Oxiplex gels, FzioMed can produce a more cost-effective solution for bone healing in spinal fusion procedures.”